The primary objective is to investigate the pharmacokinetics of AZD1981 given in different formulations and to measure renal clearance
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
14
Research Site
Uppsala, Sweden
PK samples for AZD1981 from both blood and urine
Time frame: Intense PK-sampling during the 24 hours following dose and additional samples up to 60 hours after dose.
Safety variables (adverse events and laboratory safety lab)
Time frame: Adverese events registered during study and vital signs and ECG at visit 1,2 ,6
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose